fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

INM

InMed Pharmaceuticals, Inc.

  ( )

Page Views : 132135

Analyst Ratings

 
Buy
Strong Buy
0%
Buy
100%
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
Sector
:
Healthcare
Industry
:
Biotechnology
Exchange
:
Nasdaq
Ticker
:
INM

vista's key points

  • InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs.
  • InMed has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.
  • Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits.
  • InMed is researching the therapeutic benefits of several rare cannabinoids and have produced a growing library of rare cannabinoid analogs for development.
  • InMed has initiated three pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa, and two preclinical programs in glaucoma and neurodegenerative disease.
  • InMed has expanded its pharmaceutical pipeline to investigate rare cannabinoids for their potential in treating neurodegenerative disease such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others.
  • InMed's wholly owned subsidiary, BayMedica, produces highly pure rare cannabinoids d9-THCV, CBC, CBDV and CBT for the consumer health and wellness industry.
  • InMed is considered a low float stock with 1.51Million shares Issued and outstanding according to their latest presentation.

vista's key points

  • InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs.
  • InMed has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.
  • Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits.
  • InMed is researching the therapeutic benefits of several rare cannabinoids and have produced a growing library of rare cannabinoid analogs for development.
  • InMed has initiated three pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa, and two preclinical programs in glaucoma and neurodegenerative disease.
  • InMed has expanded its pharmaceutical pipeline to investigate rare cannabinoids for their potential in treating neurodegenerative disease such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others.
  • InMed's wholly owned subsidiary, BayMedica, produces highly pure rare cannabinoids d9-THCV, CBC, CBDV and CBT for the consumer health and wellness industry.
  • InMed is considered a low float stock with 1.51Million shares Issued and outstanding according to their latest presentation.

Sector
:
Healthcare
Industry
:
Biotechnology
Exchange
:
Nasdaq
Ticker
:
INM

company profile

 

InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. They also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.  

Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits. InMed has initiated three pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa, and two preclinical programs in glaucoma and neurodegenerative disease.

Unlike natural cannabinoids isolated from the plant which are not patentable, InMed’s proprietary cannabinoid analogs are patentable and are recognized as new chemical entities (NCEs). These analogs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cannabinoid with modifications that may make them preferred candidates to treat specific diseases. They are screening these analogs for their therapeutic properties and pharmaceutical development.

InMed’s subsidiary, BayMedica, is producing a portfolio of premium rare cannabinoids as raw ingredients for your health and wellness products. They have engineered bioidentical cannabinoids with high purity and consistency, and free of THC. they currently manufacture the rare, minor cannabinoids cannabichromene (CBC), tetrahydrocannabivarin (d9-THCV), cannabidivarin (CBDV) and cannabicitran (CBT) which are available for B2B purchase.

www.inmedpharma.com.

vista's view

InMed Pharmaceuticals (“InMed”) is a publicly traded company on the Nasdaq that trades under the symbol INM. InMed is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs....

Read More

vp watchlist

The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.